Gene · 8065
Papers1,704
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,704
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation. | Blood | 2026 | 42640860 | PubTator, text mining | PubMed |
| Neddylation-dependent RAB40-Cullin5 E3 ligase complex controls ubiquitin-mediated proteasomal degradation of DNAJC13. | BBA Adv | 2026 | 42602476 | PubTator, text mining | PubMed |
| Discovery of spirocyclic amide scaffolds as novel neddylation E1 inhibitors to suppress the growth and survival of lung cancer cells. | RSC Med Chem | 2026 | 42559520 | PubTator, text mining | PubMed |
| A de novo designed enzyme for photo-proximity labeling of E3 ligase neighborhoods in live cells. | bioRxiv | 2026 | 42538903 | PubTator, text mining | PubMed |
| Structure of the E3 ligase CRL2ZYG11B with substrates reveals the molecular basis for N-degron recognition and ubiquitination. | Cell Rep | 2026 | 42224082 | PubTator, text mining | PubMed |
| Targeting UBE2F induces a resilience program enhancing CD8 T cell immunity. | J Exp Med | 2026 | 42188874 | PubTator, text mining | PubMed |
| Cysteine availability tunes ubiquitin signaling via inverse stability of LRRC58 E3 ligase and its substrate CDO1. | Nat Commun | 2026 | 42098103 | PubTator, text mining | PubMed |
| ASB7 promotes osteosarcoma lung metastasis through ubiquitin-mediated degradation of ATF2. | Cell Discov | 2026 | 42086529 | PubTator, text mining | PubMed |
| CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues. | Front Med (Lausanne) | 2026 | 42078440 | PubTator, text mining | PubMed |
| In silico analysis of gene expression signatures and drug repurposing associated with metastatic progression in melanoma (skin cancer). | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42068380 | PubTator, text mining | PubMed |
| Cul5: immune cell function and therapeutic potential. | Front Immunol | 2026 | 42064089 | PubTator, text mining | PubMed |
| A comprehensive analysis of the Cullin family reveals that CUL5 and CUL7 promote colorectal cancer progression and serve as prognostic markers. | Hereditas | 2026 | 42021323 | PubTator, text mining | PubMed |
| ASB9 promotes ubiquitin-mediated degradation of TNP2 to facilitate histone-to-protamine transition in humans and mice. | Proc Natl Acad Sci U S A | 2026 | 41915740 | PubTator, text mining | PubMed |
| Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in immunotherapy and biomarker potentials. | Cancer Immunol Immunother | 2026 | 41915211 | PubTator, text mining | PubMed |
| Regulation of Cellular Signaling by CUL5 is Dependent on Its Neddylation Status. | Cell Physiol Biochem | 2026 | 41797611 | PubTator, text mining | PubMed |
| The roles of post-translational modifications in the pathogenesis of RNA viruses: allies or adversaries? | Front Microbiol | 2026 | 41767575 | PubTator, text mining | PubMed |
| ZOMES: expanding roles of the PCI complexes from protein metabolism to drug discovery. | NPJ Metab Health Dis | 2026 | 41760881 | PubTator, text mining | PubMed |
| Rewriting the viral script: post-translational modifications orchestrating SARS-CoV-2 pathogenesis and immune evasion. | Front Microbiol | 2026 | 41743132 | PubTator, text mining | PubMed |
| Ubiquitination at pericentromeric regions: directing heterochromatin reassembly during cell division. | Signal Transduct Target Ther | 2026 | 41714594 | PubTator, text mining | PubMed |
| CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy. | PLoS Biol | 2026 | 41662369 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8065/papers